Hedlund P O
Urologiska kliniken, Karolinska sjukhuset, Stockholm.
Lakartidningen. 2000 Aug 9;97(32-33):3466-9.
In advanced prostate cancer when the tumor has metastasized, endocrine therapy is the primary treatment alternative. Endocrine therapy was introduced 60 years ago by Huggins and Hodges in the form of castration or estrogen treatment. Unfortunately we must now concede that no decisive breakthrough in the pharmacological treatment of prostate cancer has occurred since that time. We do have several different endocrine treatment alternatives at our disposal today--all with varying advantages and drawbacks. We do, however, eagerly await new therapeutic options for the pharmacological eradication of prostatic adenocarcinoma. Today our interest is focused on methods of tailoring endocrine therapy in ways that offer the individual patient an optimal combination of quality of life and anticancer efficacy. The various opinions and research results which inform current strategies of endocrine therapy are described briefly.
在晚期前列腺癌发生转移时,内分泌治疗是主要的治疗选择。60年前,哈金斯和霍奇斯以去势或雌激素治疗的形式引入了内分泌治疗。遗憾的是,我们现在不得不承认,自那时以来,前列腺癌的药物治疗并未取得决定性突破。如今我们确实有几种不同的内分泌治疗选择——各有不同的优缺点。然而,我们急切地期待着用于根除前列腺腺癌的新治疗方案。目前我们的兴趣集中在调整内分泌治疗的方法上,以便为个体患者提供生活质量和抗癌疗效的最佳组合。本文简要介绍了为当前内分泌治疗策略提供依据的各种观点和研究结果。